Private equity firm acquires Welsh CRO Simbec-Orion for undisclosed price

handshake
The CBPE deal for Simbec-Orion will provide funding for international expansion for the CRO, particularly in the U.S. and European markets. (Pixabay/geralt)

Welsh CRO Simbec-Orion was acquired by U.K.-based private equity firm CBPE Capital for an undisclosed price.

The acquisition, which was made via a management buyout through CPBE’s Capital Fund IX, acquired the shareholding of the Wales Life Sciences Investment Fund (WLSIF) that was managed by Arix Capital Management, a subsidiary of Arix Bioscience, the company said. The CRO was formed in 2014 with the merger of Simbec Research and Orion Clinical in a deal funded by WLSIF, which had acquired Simbec in 2013.

The CBPE deal for Simbec-Orion will provide funding for international expansion for the CRO, particularly in the U.S. and European markets.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“The combination of Simbec Research and Orion Clinical provided the base to create a growing CRO in the midmarket,” Ronald Openshaw, Simbec-Orion’s chief executive, said in a statement. “We are delighted to secure this return for the WLSIF and have clear plans with CBPE for the future growth of the group.”

Simbec-Orion, which is a full service CRO across all stages of development through phases 1, 2 and 3, focuses on biotech companies and small-cap, specialty and mid-cap pharma companies. Its main concentrations are in oncology, rare diseases and orphan drugs, respiratory conditions and translational medicine.

Suggested Articles

Qiagen is collaborating with Ares Genetics to develop new bioinformatics and assay solutions for research targeting antibiotic-resistant bacteria.

STA Pharmaceutical has signed an exclusive technology and marketing deal with Swiss biotech BioLingus.

Clinerion is partnering with Citeline to give clinical researchers a more comprehensive approach to making evidence-based decisions.